Preparation of a Novel Oat β-Glucan–Chromium(III) Complex and Its Hypoglycemic Effect and Mechanism
Molecules · 2024
DOI: 10.3390/molecules29091998 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Pengshou Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Food and Drug, Luoyang Normal University, Luoyang 471934, China. Hauptthemen laut MEDLINE: Chromium, Hypoglycemic Agents, beta-Glucans, alpha-Glucosidases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Public Welfare Research Institutes, 2023 Henan Province University Student Innovation and Entrepreneurship Key Project, Special Project of Henan Provincial Key Research, Development and Promotion (Science and Technology).
Abstract (Originalsprache)
This study synthesized a novel oat β-glucan (OBG)-Cr(III) complex (OBG-Cr(III)) and explored its structure, inhibitory effects on α-amylase and α-glucosidase, and hypoglycemic activities and mechanism in vitro using an insulin-resistant HepG2 (IR-HepG2) cell model. The Cr(III) content in the complex was found to be 10.87%. The molecular weight of OBG-Cr(III) was determined to be 7.736 × 104 Da with chromium ions binding to the hydroxyl groups of OBG. This binding resulted in the increased asymmetry and altered spatial conformation of the complex along with significant changes in morphology and crystallinity. Our findings demonstrated that OBG-Cr(III) exhibited inhibitory effects on α-amylase and α-glucosidase. Furthermore, OBG-Cr(III) enhanced the insulin sensitivity of IR-HepG2 cells, promoting glucose uptake and metabolism more efficiently than OBG alone. The underlying mechanism of its hypoglycemic effect involved the modulation of the c-Cbl/PI3K/AKT/GLUT4 signaling pathway, as revealed by Western blot analysis. This research not only broadened the applications of OBG but also positioned OBG-Cr(III) as a promising Cr(III) supplement with enhanced hypoglycemic benefits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Food and Drug, Luoyang Normal University, Luoyang 471934, China.
- Cancer Institute, Fudan University Cancer Hospital and Cancer Metabolism Laboratory, Institutes of Biomedical Sciences, Fudan University, Shanghai 200032, China.
- Experimental Research Center, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Förderung
- Fundamental Research Funds for the Central Public Welfare Research Institutes
- 2023 Henan Province University Student Innovation and Entrepreneurship Key Project
- Special Project of Henan Provincial Key Research, Development and Promotion (Science and Technology)
- Key Scientific Research Projects of Henan Province Colleges and Universities
- National Level Project Cultivation Fund of Luoyang Normal University
- Ph.D. Research Foundation of Luoyang Normal University
Zitieren
APA
Li, P., Wang, Y., Wang, X., Li, R., Wang, K., Jiang, Y., Zhang, M., Huang, C., Ma, Q., Sun, J., & Quan, J. (2024). Preparation of a Novel Oat β-Glucan–Chromium(III) Complex and Its Hypoglycemic Effect and Mechanism. Molecules. https://doi.org/10.3390/molecules29091998
Vancouver
Li P, Wang Y, Wang X, Li R, Wang K, Jiang Y, et al. Preparation of a Novel Oat β-Glucan–Chromium(III) Complex and Its Hypoglycemic Effect and Mechanism. Molecules. 2024. doi:10.3390/molecules29091998
BibTeX
@article{Li2024,
author = {Li, Pengshou and Wang, Yunlu and Wang, Xiaoting and Li, Rui and Wang, Kaihui and Jiang, Yu and Zhang, Mingyuan and Huang, Chuhan and Ma, Qixiang and Sun, Jian and Quan, Jianye},
title = {Preparation of a Novel Oat β-Glucan–Chromium(III) Complex and Its Hypoglycemic Effect and Mechanism},
journal = {Molecules},
year = {2024},
doi = {10.3390/molecules29091998}
}
EUVIMED